Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men.

Iranmanesh A, Bowers CY, Veldhuis JD

The Journal of clinical endocrinology and metabolism1 Sept 2004Cited by 8 (Europe PMC)

PMID15356066DOI10.1210/jc.2004-0205PepBankPUB-15356066

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

01HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
In healthy men, octreotide reduced GHRP‑2-stimulated GH secretory burst mass.
In plain wordsIn healthy men, octreotide lowered the amount of growth hormone released in bursts after a GHRP‑2 dose.
Peptide
GHRP-2
Outcome
DecreaseGHRP-2-stimulated GH secretory burst mass after octreotide
Study
n = 10
Comparator
GHRP-2 without octreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH secretory burst mass
28
GHRP-2 alone
GH secretory burst mass
18
GHRP-2 with octreotide
Source sentences
Summary
In the GHRP-2-stimulated setting, presumptive SSTR-2/-5 agonism suppressed all three GH secretory burst masses, from 28 +/- 3.2 to 18 +/- 2.0 (P = 0.045); GH pulse frequency, from 3.3 +/- 0.30 to 2.0 +/- 0.18 (P = 0.0025); and the irregularity (approximate entropy) of GH release, from 0.648 +/- 0.04…
2 context sentences(design, population, supporting numbers)
Summary · context
To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fasting morning infusion sessions.
Summary · context
Interventions comprised sc administration of octreotide (1 microg/kg), followed by bolus iv injection of saline, GHRH (1 microg/kg), GHRP-2 (1 microg/kg), or both peptides.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1535606601
02HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
In healthy men, octreotide reduced the frequency of GHRP‑2-stimulated GH pulses.
In plain wordsIn healthy men, octreotide lowered how often growth hormone pulses occurred after a GHRP‑2 dose.
Peptide
GHRP-2
Outcome
DecreaseGHRP-2-stimulated GH pulse frequency after octreotide
Study
n = 10
Comparator
GHRP-2 without octreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
GH pulse frequency
3.3
GHRP-2 alone
GH pulse frequency
2
GHRP-2 with octreotide
Source sentences
Summary
In the GHRP-2-stimulated setting, presumptive SSTR-2/-5 agonism suppressed all three GH secretory burst masses, from 28 +/- 3.2 to 18 +/- 2.0 (P = 0.045); GH pulse frequency, from 3.3 +/- 0.30 to 2.0 +/- 0.18 (P = 0.0025); and the irregularity (approximate entropy) of GH release, from 0.648 +/- 0.04…
2 context sentences(design, population, supporting numbers)
Summary · context
To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fasting morning infusion sessions.
Summary · context
Interventions comprised sc administration of octreotide (1 microg/kg), followed by bolus iv injection of saline, GHRH (1 microg/kg), GHRP-2 (1 microg/kg), or both peptides.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1535606602
03HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
In healthy men, octreotide reduced the irregularity (approximate entropy) of GHRP‑2-stimulated GH release.
In plain wordsIn healthy men, octreotide made growth hormone release after a GHRP‑2 dose less irregular.
Peptide
GHRP-2
Outcome
DecreaseIrregularity of GHRP-2-stimulated GH release after octreotide
Study
n = 10
Comparator
GHRP-2 without octreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Approximate entropy
0.648
GHRP-2 alone
Approximate entropy
0.433
GHRP-2 with octreotide
Source sentences
Summary
In the GHRP-2-stimulated setting, presumptive SSTR-2/-5 agonism suppressed all three GH secretory burst masses, from 28 +/- 3.2 to 18 +/- 2.0 (P = 0.045); GH pulse frequency, from 3.3 +/- 0.30 to 2.0 +/- 0.18 (P = 0.0025); and the irregularity (approximate entropy) of GH release, from 0.648 +/- 0.04…
2 context sentences(design, population, supporting numbers)
Summary · context
To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fasting morning infusion sessions.
Summary · context
Interventions comprised sc administration of octreotide (1 microg/kg), followed by bolus iv injection of saline, GHRH (1 microg/kg), GHRP-2 (1 microg/kg), or both peptides.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1535606603
04HumanNot a test of GHRP-2 aloneRandomized controlled trialMechanism
In healthy men, with GHRH alone or GHRH plus GHRP‑2 as the stimulus, octreotide decreased only GH secretory burst mass.
In plain wordsIn healthy men, octreotide lowered only the amount of growth hormone released per burst after GHRH or GHRH plus GHRP‑2.
Peptide
GHRP-2
Outcome
DecreaseGHRH and GHRH/GHRP-2-stimulated GH burst mass after octreotide
Study
n = 10
Comparator
Without octreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
In contrast, in the GHRH and combined GHRH/GHRP-2-stimulated contexts, octreotide decreased only GH secretory burst mass (P = 0.047).
2 context sentences(design, population, supporting numbers)
Summary · context
To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fasting morning infusion sessions.
Summary · context
Interventions comprised sc administration of octreotide (1 microg/kg), followed by bolus iv injection of saline, GHRH (1 microg/kg), GHRP-2 (1 microg/kg), or both peptides.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1535606604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.